Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.

ABSTRACT: The extent to which PSA screening is related to prostate cancer mortality reduction in the United States (US) is controversial. US Surveillance, Epidemiology, and End Results Program (SEER) data from 1980 to 2016 were examined to assess the relationship between prostate cancer mortality and cumulative excess incidence (CEI) in the PSA screening era and to clarify the impact of race on this relationship. CEI was considered as a surrogate for the intensity of prostate cancer screening with PSA testing and subsequent biopsy as appropriate. Data from 163,982,733 person-years diagnosed with 544,058 prostate cancers (9 registries, 9% of US population) were examined. Strong inverse linear relationships were noted between CEI and prostate cancer mortality, and 317,356 prostate cancer deaths were a

SUBMITTER: McLaughlin PW 

PROVIDER: S-EPMC10925039 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature